Literature DB >> 19915977

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.

Brenda Cohen1, Mamiko Shimizu, Julia Izrailit, Nancy F L Ng, Yuri Buchman, James G Pan, Judy Dering, Michael Reedijk.   

Abstract

The Notch ligand, JAG1 is associated with breast cancer recurrence. Herein, we report on a genomics approach to elucidate mechanisms downstream of JAG1 that promote breast cancer growth. In a survey of 46 breast cancer cell lines, we found that triple negative (TN; basal and mesenchymal ER-, PR-, and Her2-negative) lines express JAG1 at significantly higher levels than do HER2(+) or luminal (ER(+)) Her2(-) cell lines. In contrast to the luminal lines tested (T47D and MCF7), TN breast cancer cell lines (HCC1143 and MDA MB231) display high-level JAG1 expression and growth inhibition with RNA interference-induced JAG1 down-regulation. We used microarray profiling of TN tumor cells transfected with JAG1 siRNA to identify JAG1-regulated genes (P <or= 0.005; fold change >or=1.5). Among JAG1-regulated genes identified, cyclin D1 was found to be a direct target of NOTCH1 and NOTCH3. We show that JAG1 down-regulation reduces direct binding of Notch to the cyclin D1 promoter, reduced cyclin D1 expression and inhibition of cell cycle progression through the cyclin D1-dependant G1/S checkpoint. Furthermore, we show that cyclin D1 and JAG1 expression correlate in TN breast cancer expression datasets. These data suggest a model whereby JAG1 promotes cyclin D1-mediated proliferation of TN breast cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915977     DOI: 10.1007/s10549-009-0621-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  66 in total

1.  Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma.

Authors:  Derek P Simon; Thomas J Giordano; Gary D Hammer
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

2.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

Authors:  Keli Xu; Jerry Usary; Philaretos C Kousis; Aleix Prat; Dong-Yu Wang; Jessica R Adams; Wei Wang; Amanda J Loch; Tao Deng; Wei Zhao; Robert Darrell Cardiff; Keejung Yoon; Nicholas Gaiano; Vicki Ling; Joseph Beyene; Eldad Zacksenhaus; Tom Gridley; Wey L Leong; Cynthia J Guidos; Charles M Perou; Sean E Egan
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

3.  The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.

Authors:  Sean A Piwarski; Chelsea Thompson; Ateeq R Chaudhry; James Denvir; Donald A Primerano; Jun Fan; Travis B Salisbury
Journal:  Biochem Pharmacol       Date:  2020-02-04       Impact factor: 5.858

4.  Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures.

Authors:  Karina Kristoffersen; Mette Villingshøj; Hans Skovgaard Poulsen; Marie-Thérése Stockhausen
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

5.  Pharmacological disruption of the Notch transcription factor complex.

Authors:  Rajwinder Lehal; Jelena Zaric; Michele Vigolo; Charlotte Urech; Viktoras Frismantas; Nadine Zangger; Linlin Cao; Adeline Berger; Irene Chicote; Sylvain Loubéry; Sung Hee Choi; Ute Koch; Stephen C Blacklow; Hector G Palmer; Beat Bornhauser; Marcos González-Gaitán; Yvan Arsenijevic; Vincent Zoete; Jon C Aster; Jean-Pierre Bourquin; Freddy Radtke
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

6.  Notch signaling in hepatocellular carcinoma: guilty in association!

Authors:  Mario Strazzabosco; Luca Fabris
Journal:  Gastroenterology       Date:  2012-10-22       Impact factor: 22.682

7.  Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.

Authors:  Shubing Zhang; Wen-cheng Chung; Lucio Miele; Keli Xu
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

Review 8.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

9.  Identification of a novel progenitor cell marker, grainyhead-like 2 in the developing pituitary.

Authors:  Whitney Edwards; Leah B Nantie; Lori T Raetzman
Journal:  Dev Dyn       Date:  2016-09-18       Impact factor: 3.780

10.  High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer.

Authors:  Julia Izrailit; Hal K Berman; Alessandro Datti; Jeffrey L Wrana; Michael Reedijk
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.